Grant: Idea to Innovation
McMaster University
$20,000.00
L2M NSERC - High Affinity Inhibitors for the Diagnosis of Heparin Induced Thrombocytopenia
EF 2022-23
Résumé
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction to the anticoagulant heparin. Immediate diagnosis and treatment is crucial as 20-50% of HIT patients will develop blood clots, which are fatal in 30% of patients. However, doctors struggle to diagnose HIT because it is difficult to detect clinically significant antibodies in patients. Most patients exposed to heparin will produce some form of antibody, but only a small percentage of these antibodies cause HIT. Currently, HIT diagnostic tests are limited by either diagnostic accuracy or performance feasibility. Immunoassay tests have high false-positive rates and cause many patients to receive unnecessary treatment. Conversely, functional tests are laborious, technically challenging, and can delay diagnosis. As such, many physicians will administer treatment before receiving laboratory confirmation, which can have adverse side-effects for patients. For hospitals, the overdiagnosis and overtreatment of HIT is also associated with an increased financial burden. To alleviate this problem, we designed an inhibitor that can be used detect the presence of disease-causing HIT antibodies by competing for their binding in a standard immunoassay. These inhibitors can be used to improve already existing immunoassay-based diagnostics to increase their current performance. Therefore, our test will have faster turn-around times and can be performed with technical ease at any clinical laboratory. This product will also provide a quick and cost-effective solution without compromising patient outcomes.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
576553-2022
Name nom
Nazy, Ishac I
Department département
Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Installment
inst:1
Partie
1
Nb partie
1
Application title
L2M NSERC - High Affinity Inhibitors for the Diagnosis of Heparin Induced Thrombocytopenia
Application summary
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction to the anticoagulant heparin. Immediate diagnosis and treatment is crucial as 20-50% of HIT patients will develop blood clots, which are fatal in 30% of patients. However, doctors struggle to diagnose HIT because it is difficult to detect clinically significant antibodies in patients. Most patients exposed to heparin will produce some form of antibody, but only a small percentage of these antibodies cause HIT. Currently, HIT diagnostic tests are limited by either diagnostic accuracy or performance feasibility. Immunoassay tests have high false-positive rates and cause many patients to receive unnecessary treatment. Conversely, functional tests are laborious, technically challenging, and can delay diagnosis. As such, many physicians will administer treatment before receiving laboratory confirmation, which can have adverse side-effects for patients. For hospitals, the overdiagnosis and overtreatment of HIT is also associated with an increased financial burden. To alleviate this problem, we designed an inhibitor that can be used detect the presence of disease-causing HIT antibodies by competing for their binding in a standard immunoassay. These inhibitors can be used to improve already existing immunoassay-based diagnostics to increase their current performance. Therefore, our test will have faster turn-around times and can be performed with technical ease at any clinical laboratory. This product will also provide a quick and cost-effective solution without compromising patient outcomes.